Skip to main content
. 2021 Jul 23;27(4):589–602. doi: 10.3350/cmh.2021.0038

Figure 5.

Figure 5.

Subgroup analysis according to Milan criteria. Time to recurrence (A) and overall survival (B) according to EVR use in patients within Milan criteria. Time to recurrence (C) and overall survival (D) according to EVR use in patients exceeding Milan criteria. EVR, everolimus.